Cancer clinical trials in the region Occitanie

385 currently recruiting clinical trials
Region Occitanie
Phase 1 / Phase 2 Lung cancer #NCT06128551
Phase 1b expansion de dose et phase 2 cohortes CBNPC non naïf d'inhibiteurs de KRAS G12C
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Revolution Medicines, Inc.
Phase 1 / Phase 2 Colon cancer Rectal cancer #NCT06934538 #2024-512011-45-00
Phase 1 et Phase 2A Bras 2A-1
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
Other KRAS KRAS G12C KRAS non G12C MSS/pMMR KRAS G12D
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
BRAF
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
5 recruiting sites
Brenus Pharma
Phase 1 / Phase 2 Lung cancer #NCT06162221
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
Other KRAS HRAS KRAS G12C KRAS non G12C KRAS G12D NRAS
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
13 recruiting sites
Revolution Medicines, Inc.
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06154291 #2023-505266-29-00
Partie I: Escalade de dose
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Xenothera SAS
Phase 1 / Phase 2 Breast cancer Lung cancer Colon cancer Rectal cancer Pancreas cancer Stomach and esophageal cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06154291 #2023-505266-29-00
Phase 1 Extension de dose
Required histologic types
NSCLC (Non-Small Cell Lung Cancer) Stomach Oesogastric junction Esophagus Epithelial ovarian cancer
Required histologic sub types
Squamous NSCLC Non-squamous NSCLC Adenocarcinoma
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Xenothera SAS
Phase 1 / Phase 2 Acute leukemia #NCT05768035
Required histologic types
Acute lymphoblastic leukemia (ALL) Acute myeloid leukemia (AML)
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive Allogeneic stem cell transplant
4 recruiting sites
Smart Immune SAS
Phase 1 / Phase 2 Lymphoma CLL & Richter's syndrome Acute leukemia #NCT04707300 #2019-004883-23
Required histologic types
CLL (Chronic Lymphocytic Leukemia) Acute lymphoblastic leukemia (ALL) Acute myeloid leukemia (AML)
4 recruiting sites
Assistance Publique - Hôpitaux de Paris
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT05356741
Required HER2 statuses
HER2 Positive
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Vir Biotechnology, Inc.
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06265727
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
Other mutation
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Corbus Pharmaceuticals Inc.
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06622486 #2024-512921-10-00
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Egle Therapeutics